1 / 16

AVE Micro Stent KFSH & RC Experience with 6 months Angiographic Follow Up

AVE Micro Stent KFSH & RC Experience with 6 months Angiographic Follow Up. Layth A. Mimish, M. Bakhshi, F. Al-Nozha, A. Kinsara, O. Amoudi, J. Buraiki, K. Niazi, B. Dunn, B. Dajani, M.E. Fawzy. AVE Micro Stent II. Arterial vascular engineering, Inc. Santa Rosa CA, USA

david-manning
Download Presentation

AVE Micro Stent KFSH & RC Experience with 6 months Angiographic Follow Up

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AVE Micro StentKFSH & RC Experience with 6 months Angiographic Follow Up Layth A. Mimish, M. Bakhshi, F. Al-Nozha, A. Kinsara, O. Amoudi, J. Buraiki, K. Niazi, B. Dunn, B. Dajani, M.E. Fawzy

  2. AVE Micro Stent II • Arterial vascular engineering, Inc. Santa Rosa CA, USA • October 1994 sales commenced • FDA study approval Nov. 1995 • 2.5 mm stent introduced Dec. 1995 • Micro stent II XL (30, 39 mm) introduced January 1996

  3. AVE Micro Stent II • 316 L stainless steel • Moderate radio-opacity • Non- Ferromagnetic • Metallic surface area 8.4% • Sinusoidal ring • 0.065 inch un-expanded profile

  4. AVE Microstent II • Excellent longitudinal flexibility • Shortenining less than 2 % • Available diameters 2.5-4 mm • Available lengths 6-39 mm • Clinical trials on peripheral stents

  5. AVE Micro Stent II • PE ( moderately compliant ) balloon • Balloon mounted stent, no sheath • Minimal ID of guider 0.072 • Proximal and distal stent end markers • Nominal deployment at 9 Atmospheres • Excellent recrossability

  6. 1st stent deployed May 1995 • Until October 1997, 340 stents were deployed in 283 patients • By October 1997, 223 patients had completed 6 months post stent deployment, and underwent angiographic follow up

  7. Demographic/ Clinical Data • 340 Stents in 283 patients • 228 Males and 55 Females • Age 55+- 13 years • Smoking in 95 patients (33%) • Diabetes in 158 (56%) • Hypertension in 166 (59%) • Hyperlipidemia in 68%

  8. Demographic/ Clinical Data • History of MI in 180 (64%), 81% of which are Q- wave MI • Previous PTCA in 76 (27%) • History of CABG surgery in 9 patients • Mean CCS Class 2.2 +- 1.1

  9. AVE Micro Stent II • Elective stenting in 214 (63%) • Stenting for Dissection 126 (37%) • Mean Stent Size 3.1 +- 0.4 mm • Mean Length 16.2 +- 5.8 mm • Mean Deployment Pressure 15.7 +- 2.3 Atmospheres

  10. Vessel Stented • Left Main 1 • LAD 163 (48%) • Diagonal 2 • Circumflex 38 (11%) • OM 15 (4%) • Intermediate 7 (2%) • RCA 114 (33%)

  11. Antiplatelet/ Anticoagulation • ASA + Warfarin in 93 initial cases • ASA, Ticlopidine, 48 hrs Heparinization • ASA, Ticlopidine, Heparin bolus only • Mean hospital stay 3.6 +-2 days

  12. Successful Procedures • Recanalization with < 20% residual stenosis, without inhospital major events ( Death, Emergency CABG, Q-MI) • Success in 329/340 stents (96.8%)

  13. Major Complications • Death in 1 patient with Acute MI, poor LV function and salvage PTCA/Stenting • Q wave MI in 3 patients • Emergency CABG surgery in 5 patients

  14. Minor Complications • Non Q MI 10 • Hypotension 3 • Haematoma 4 • Pseudo aneurysm 1 • Subacute Occlusion 3 • Loss of stent 1 • Sepsis 1

  15. 6 month follow up • 222 /340 completed 6 months • 79/222 restenosed angiographicaqlly (35%) • Elective stenting restenosis 57/162 (35%) • Dissection stenting restenosis 22/60(37%) • restenotic lesion stenting restenosis 19/50 (38%) vs. (35%)

  16. Conclusion • All purpose stent • Excellent success rates • Easy deployment even in very complex lesions • Higher restenosis rate in this study compared to others !!!

More Related